Sloss, Callum M.
Merrimack Pharmaceuticals (United States)
2 papers on CoChat
Most cited papers
- Verified
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research
Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers
Cited by 742
- Verified
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
Lieu, C. H., Beeram, M., Harb, W. A., Kearns, J. D., Sloss, C. M., Nering, R., Adjei, A. A., & Wolf, B. B. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free